Sara Hurvitz

35PUBLICATIONS
200CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Jul 13, 2026
Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape.

|Jun 15, 2026
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Mar 09, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano

|Jun 25, 2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.

Aditya Bardia, Hope S Rugo, Mina S Sedrak

|Mar 17, 2025
TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs.

William R Gwin, Sara A Hurvitz

Pageof 6

Frequent Collaborators

10 joint publications

Hope S Rugo

7 joint publications

Aditya Bardia

7 joint publications

Véronique Diéras

7 joint publications

Javier Cortés